| Literature DB >> 17497182 |
Albertien M van Eerde1, Bobby P C Koeleman, Jiddeke M van de Kamp, Tom P V M de Jong, Cisca Wijmenga, Jacques C Giltay.
Abstract
Vesico-ureteral reflux (VUR) is a major contributing factor to end-stage renal disease in paediatric patients. Primary VUR is a familial disorder, but little is known about its genetic causes. To investigate the involvement of 12 functional candidate genes and two reported loci in VUR, we performed a linkage study in four large, Dutch, multi-generational families with multiple affected individuals. We were unable to detect linkage to any of the genes and loci and could exclude the GDNF, RET, SLIT2, SPRY1, PAX2, AGTR2, UPK1A and UPK3A genes and the 1p13 and 20p13 loci from linkage to VUR. Our results provide further evidence that there appears to be genetic heterogeneity in VUR.Entities:
Mesh:
Year: 2007 PMID: 17497182 PMCID: PMC1915619 DOI: 10.1007/s00467-007-0492-4
Source DB: PubMed Journal: Pediatr Nephrol ISSN: 0931-041X Impact factor: 3.714
Genes tested in linkage study of four large multi-generational VUR families (LOD logarithm of the odds, NPL non-parametric linkage, HLOD heterogeneity LOD, A ureteral budding, BRET/GDNF pathway, C mouse and human phenotype, D linkage study, E in urothelial plaque with UPK3A (mouse model), F mouse model.)
| Gene | Relevance | Chromosome | Location (cM) | Multi-point LOD score at the gene location | NPL | NPL | Alphab | HLODb | Reference |
|---|---|---|---|---|---|---|---|---|---|
| A/B | 5 | 54 | −2.03 | 0.70 | 0.22 | 0.10 | 0.01 | [ | |
| A/B | 10 | 66 | −2.55 | −0.85 | 0.80 | 0.00 | 0.00 | [ | |
| A/B | 4 | 34 | −2.15 | 0.35 | 0.32 | 0.15 | 0.80 | [ | |
| A/B | 4 | 126 | −3.25 | −0.98 | 0.86 | 0.00 | 0.00 | [ | |
| A/B | 10 | 124 | −3.43 | −0.49 | 0.63 | 0.00 | 0.00 | [ | |
| A/C | X | 71 | −3.81 | −1.18 | 0.88 | 0.00 | 0.00 | [ | |
| D | 6 | 46 | −1.84 | 0.25 | 0.35 | 0.20 | 0.16 | [ | |
| E | 19 | 61 | −2.90 | −0.62 | 0.69 | 0.00 | 0.00 | [ | |
| E | 3 | 138 | 0.15 | 1.24 | 0.12 | 0.65 | 0.43 | [ | |
| E | 11 | 115 | −1.50 | −0.22 | 0.52 | 0.00 | 0.00 | [ | |
| A/F | 22 | 53 | −3.40a | −1.20 | 0.80 | 0.00 | 0.00 | [ | |
| E | 7 | 89 | −1.08 | 0.59 | 0.25 | 0.00 | 0.00 | [ |
aTwo-point analysis of marker D22S928; 0.5 cM away from UPK3A.
bAlpha: estimated proportion of families linked to result in corresponding heterogeneity LOD (HLOD). HLOD analyses were performed, but did not contribute and are not discussed.
Fig. 1VUR family pedigrees (21 affected individuals in 51 samples). Family 1: 2 left kidney had to be removed at 5 years; 3, 4 end-stage renal disease (ESRD); 9 VUR and ESRD; 15 VUR and duplex collecting system; 19 VUR; 18 VUR and nephropathy. Family 2: 68, 69, 73 not included in analyses; 25, 26, 30 and 31 VUR; 33 VUR and dysfunctional voiding. Family 3: 39, 42, 43 VUR and dysfunctional voiding symptomatology; 47 VUR, dysfunctional voiding, meatal stenosis. Family 4: 50 and 52 recurrent urinary tract infections (UTIs) as a child, duplex collecting system; 55 UTIs and urinary tract operation; 49 VUR; 51 VUR and dysfunctional voiding symptomatology
Fig. 2Multi-point LOD plots for the reported loci tested in the linkage study of four large multi-generational VUR families. Because one of the flanking markers of the 1p13 locus proved to actually map to chromosome 2, we also tested the chromosome 2q11 region. HLOD (heterogeneity LOD) analyses did not contribute. Positions in cM